Plant Advanced Technologies SA (ALPAT) Fair Value & Analysis
Healthcare · FR · Market cap €7.8M
Fair value as of: Jun 25, 2026
Analysis
Plant Advanced Technologies SA (ALPAT) currently trades at €5.20, while our model-based Fair Value estimate is €8.59 — implying the stock looks roughly 65.2% undervalued today. We read business quality at 93/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
About the company
Plant Advanced Technologies SA, a plant biotechnology company, produces and sells actives for cosmetic, pharmaceutical, and agrochemical markets in France. Its technologies include Process PAT Exudactive a sustainable sourcing solution to produce your exclusive, personalized Exudactive; and PAT Target Binding, which finds the ligands that bind to the protein targets of interest, such as enzymes. Plant Advanced Technologies SA was incorporated in 2005 and is headquartered in Vand"uvre-lès-Nancy, France.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Plant Advanced Technologies SA (ALPAT) undervalued?
What is the fair value of ALPAT?
What is the quality score of ALPAT?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.